Abametapir

Abametapir
Clinical data
Trade names	Xeglyze
Other names	Ha44
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Abametapir;
Routes of; administration	Topical
Drug class	Pediculicide, metalloproteinase inhibitor
ATC code	P03AX07 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	91.3–92.3%
Metabolism	CYP1A2
Metabolites	Hydroxyl and carboxyl derivatives
Elimination half-life	21 hours
Identifiers
	IUPAC name 5,5'-dimethyl-2,2'-bipyridine;
CAS Number	1762-34-1;
PubChem CID	15664;
DrugBank	DB11932;
ChemSpider	14899;
UNII	6UO390AMFB;
KEGG	D10687;
ChEMBL	ChEMBL2205807;
PDB ligand	EI3 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID00170095 ;
ECHA InfoCard	100.157.434
Chemical and physical data
Formula	C12H12N2
Molar mass	184.242 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CN=C(C=C1)C2=NC=C(C=C2)C;
	InChI InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3; Key:PTRATZCAGVBFIQ-UHFFFAOYSA-N;

Abametapir, sold under the brand name Xeglyze, is a medication used for the treatment of head lice infestation in people six months of age and older.

The most common side effects include skin redness, rash, skin burning sensation, skin inflammation, vomiting, eye irritation, skin itching, and hair color changes.

Abametapir is a metalloproteinase inhibitor. Abametapir was approved for medical use in the United States in July 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.